Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.
Goldman Sachs raised the firm’s price target on Arrowhead (ARWR) to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the ...
Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $70 from $45 and keeps an Overweight rating on the ...
The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback